Complement split products and the pathogenesis of SLE.
D000706:Anaphylatoxins / Q000032:analysis* / Q000502:physiology; D000818:Animals; D000906:Antibodies / Q000032:analysis; D001120:Arginine; D015415:Biomarkers / Q000032:analysis; D002493:Central Nervous System Diseases / Q000209:etiology / Q000276:immunology; D003167:Complement Activation; D003176:Complement C3 / Q000032:analysis* / Q000502:physiology; D015926:Complement C3a; D003182:Complement C5 / Q000032:analysis* / Q000502:physiology; D015936:Complement C5a; D003170:Complement Pathway, Alternative / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D009503:Neutropenia / Q000209:etiology; D010455:Peptides / Q000032:analysis*; D011247:Pregnancy; D011817:Rabbits
D000706:Anaphylatoxins; D000906:Antibodies; D015415:Biomarkers; D003176:Complement C3; D003182:Complement C5; D010455:Peptides; D015926:Complement C3a; D015936:Complement C5a; D001120:Arginine